media – Page 620 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

New cell death mechanism revealed

New research reveals how a dysfunction in the brain's so-called self-digestion system leads to cell death in neurodegenerative disorders. The newly discovered mechanism may lead to new therapies for conditions such as Parkinson's and Alzheimer's disease.
- Source: drugdu
- 723
- November 24, 2017
autophagy Dementia Huntington’s Disease neurodegenerative Parkinson's
Investors place bet on Chinese drugmakers

Chinese biotech groups are on target to raise about $10bn this year from venture capital funding, initial public offerings and licensing deals with overseas pharma companies, in what is partly a bet that Chinese-developed drugs can compete globally.
- Source: ft
- 877
- November 24, 2017
China drug innovation pharmaceutical R&D
Allegoric Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia

Allergan plc (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for VRAYLAR™ (cariprazine) for the maintenance treatment of adults with schizophrenia. VRAYLAR is also approved in the U.S. in adults for the acute treatment of schizophrenia and acute treatment of manic or mixed episodes of bipolar I disorder.
- Source: Allergan
- 483
- November 24, 2017
bipolar I disorder FDA schizophrenia VRAYLAR™
Pfizer and Genentech Duke it Out in Court Over Herceptin Biosimilar Patents

On Friday, November 17, Genentech, a Roche company, sued Pfizer in a federal court in Wilmington, Delaware, over Pfizer’s biosimilar for Genentech’s Herceptin. Genentech is claiming that Pfizer’s proposed biosimilar infringes 40 of its patents. Genentech also is demanding compensation for lost sales if Pfizer launches its copycat version before the Herceptin patents expire.
- Source: Biospace
- 651
- November 24, 2017
biosimilar Company Insight FDA Genentech herceptin Pfizer Roche
Encouraging oxygen’s assault on iron may offer new way to kill lung cancer cells

Blocking the motion of a key protein frees oxygen to injury iron-dependent proteins in lung and breast cancer cells, slowing their enlargement and making them more straightforward to kill.
- Source: medical-newspaper
- 567
- November 24, 2017
breast cancer lung cancer Researches
Stress in pregnancy linked to changes in infant’s nervous system, less smiling, less resilience

Maternal stress during the second trimester of pregnancy may influence the nervous system of the developing child, both before and after birth, and may have subtle effects on temperament, resulting in less smiling and engagement, as well as diminished ability to regulate emotions.
- Source: medicalxpress
- 436
- November 24, 2017
Maternal stress pregnancy Researches
Massachusetts’ Entasis Snags $31.9 Million To Advance Anti-infective Therapeutic Portfolio

“We welcome this strong support from a group of experienced and successful investors who understand the need and market opportunity for new medicines to combat multi drug-resistant bacterial infections”
- Source: biospace
- 493
- November 23, 2017
anti-infective drug-resistant Gram-negative infections Market Views
FDA approves first implanted lens that can be adjusted after cataract surgery to improve vision without eyeglasses in some patients

The U.S. Food and Drug Administration(FDA) today approved the RxSight Inc. Light Adjustable Lens and Light Delivery Device, the first medical device system that can make small adjustments to the artificial lens' power after cataract surgery so that the patient will have better vision when not using glasses.
- Source: Prnewswire
- 525
- November 23, 2017
cataract FDA Light Adjustable Lens Light Delivery Device medical device
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC

The latest BTD was granted for the treatment of adult patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have not received prior treatment with an ALK inhibitor.
- Source: Roche
- 571
- November 23, 2017
anaplastic lymphoma kinase Company Insight FDA non-small cell lung cancer Roche
Using digital pills, researchers find patients consume fewer opioids than expected

The team found that most participants opted to use opioids during the first three days following discharge from the emergency department and that on average, patients took just six pills, despite being given 21.
- Source: Drugdeliverybusine
- 425
- November 23, 2017
etectRx‘s ID-Cap system opioid Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.